Skip to content
Company Analysis

Corcept Therapeutics Incorporat CORT

A comprehensive view of key metrics, scores, and financial health for Corcept Therapeutics Incorporat

Overview of Corcept Therapeutics Incorporated

CORT NCM
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Mid Cap
Corcept Therapeutics Incorporated (CORT), is a Mid Cap company, in the Biotechnology industry, last closed at $80.46, about 82.5% overvalued vs fair value, +10.1% 1Y return, placing in the top 25% of its sector.
Metrics P/E 41.9× Rev Growth 12.8% ROE 15.0% Gross Margin 98.3%
USD 80.46
-0.81%
(Delayed)
• Vol 90d: 69.4%
52-Week Range
Market Cap
$8.70B
Enterprise Value
$8.59B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Excellent
Health
Good
Efficiency
Fair
Valuation
Good
Growth
Fair
Profitability
Excellent
Health
Good
Efficiency
Fair
Valuation
Good
Completeness: 82%
Confidence: 91%
Updated: Oct 31
Top Beats
No strong beats yet

Quick Facts

Website https://www.corcept.com
HQ Redwood City, CA
Employees 730
Fiscal year Dec 31

Next Events

Earnings Nov 3 Call: Nov 3

Fair Value Snapshot

Bear Base Bull
$13
$14
$16
Current: $80.46 -83% vs base

Engine Room Money Flow™

Mid Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$120.5M
-5.6%%
Total Revenue
$761.4M
12.8%%
Net Income
$99.7M
-29.4%%
Operating Expense
$703.6M
33.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

R&D Intensity
36.2%
Fair

Moderate R&D intensity

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Corcept Therapeutics Incorporat's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
78
/100
Strong
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.97), demonstrating pricing resilience across cycles.
  • ROIC Sustainably Above Peers ROIC at 82.4th percentile exceeds peers and WACC, demonstrating superior capital allocation.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
84
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 67% Coverage
Trade-Off Triangle Visualization A ternary plot showing CORT's balance between Growth (38.9%), Profitability (22.5%), and Safety (38.6%). Growth 39% Safety 39% Profitability 23%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

57th percentile vs peers
58
Key Signals
TSR 3.7% 57p
Strengths
  • Conservative leverage compared to industry peers
Risks

No significant risks identified for this axis.

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

57th percentile vs peers
57
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Corcept Therapeutics Incorporat.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$14.11
- - -
-82.5% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000